Here you will find the Funding Position of CCG Commissioned High-Cost Drugs within the Lancashire and South Cumbria Health Economy
A number of High-Cost Drugs, devices, procedures and products have been excluded from the scope of the national tariff of Payment by Results. These are listed on tab 13b of the following document:
2024/25 Annex A: The national tariff workbook
High-cost drugs are commissioned by:
The funding position of medicines directly commissioned by NHS England can be accessed via the NHS England website
Refer to the Manual for Prescribed Specialised Services for further information about prescribed specialised services, some of which are directly commissioned by NHS England and some by CCGs.
Date Posted: 22 - Oct - 2024
Approval Mechanism: Blueteq
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval Blueteq Form Available
Rheumatoid arthritis (LSCMMG pathway)
Date Posted: 01 - Sep - 2018
Approval Mechanism: Blueteq
Autoimmune haemolytic anaemia
Date Posted: 01 - Sep - 2018
Approval Mechanism: Blueteq
Idiopathic thrombocytopenia purpura
Date Posted: 01 - Jul - 2018
Approval Mechanism:
Membranous glomerulonephritis
Date Posted: 01 - Jul - 2018
Approval Mechanism:
Relapsing steroid sensitive nephrotic syndrome in adults
Date Posted: 01 - Nov - 2018
Approval Mechanism: Blueteq
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (NICE TA221)
Date Posted: 15 - Jul - 2022
Approval Mechanism:
Date Posted: 14 - Sep - 2022
Approval Mechanism: Blueteq form
Date Posted: 01 - Dec - 2017
Approval Mechanism: Prior Approval Blueteq Form Available
Rheumatoid arthritis (LSCMMG pathway)
Date Posted: 01 - Oct - 2017
Approval Mechanism: Blueteq
Date Posted: 01 - Sep - 2015
Approval Mechanism: Blueteq
Moderate to Severe Plaque Psoriasis (NICE TA350)
Date Posted: 01 - Oct - 2016
Approval Mechanism: Blueteq
Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (NICE TA407)
Date Posted: 01 - Jun - 2017
Approval Mechanism: Blueteq
Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)
Date Posted: 01 - Apr - 2016
Approval Mechanism: N/A
Narcolepsy with cataplexy
Date Posted: 11 - Feb - 2022
Approval Mechanism: Blueteq form
Date Posted: 17 - Mar - 2023
Approval Mechanism: Blueteq
Date Posted: 01 - May - 2013
Approval Mechanism: Blueteq
Adult growth hormone deficiency (NICE TA64) & Growth failure in children (NICE TA188)
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval Blueteq Form Available
Date Posted: 01 - May - 2019
Approval Mechanism: Prior Approval Blueteq Form Available
